Supriya Lifescience · NSE: SUPRIYA · BSE: 543434
Q1 FY25 results · Apr–Jun 2024
Supriya Lifescience reported revenue from operations of ₹160.63 crore (up 21.7% from Q1 FY24) and net profit of ₹44.64 crore (up 56.6% from Q1 FY24) for Q1 FY25 (Apr–Jun 2024), on a standalone basis.
| Item | Q1 FY25 | Q1 FY24 | YoY | Q4 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 160.63 | 132.02 | +21.7% | 158.18 | +1.5% |
| Other income | 2.22 | 2.92 | −23.8% | 2.19 | +1.8% |
| Total income | 162.85 | 134.94 | +20.7% | 160.37 | +1.5% |
| Profit before tax | 59.77 | 42.64 | +40.2% | 53.17 | +12.4% |
| Net profit for the period | 44.64 | 28.51 | +56.6% | 36.93 | +20.9% |
| EPS, basic (₹) | 5.54 | 3.54 | +56.5% | 4.59 | +20.7% |
| Net margin (%) | 27.8 | 21.6 | 23.3 |
Standalone
- Filed with BSE
- 24 Aug 2024, 11:30 IST
- Board meeting
- 10 Aug 2024
- Period
- 01 Apr 2024 to 30 Jun 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE